The biotechnology revolution: implications for the pharmaceutical industry
by Bianca S. Piachaud, Matthew G. Lynas
International Journal of Biotechnology (IJBT), Vol. 3, No. 3/4, 2001

Abstract: Until recently, many of the larger pharmaceutical companies were exclusively responsible for the discovery of novel treatments through the efforts of their own in-house research. However, the arrival of biotechnology was to change these traditional patterns of innovation. Today, pharmaceutical manufacturers no longer view themselves as the sole innovators in the industry. Rather, they are increasingly relying on small firms for drug discovery, while concentrating on their core competencies for drug development and marketing. The emergence of these smaller firms that comprise the biotech sector has facilitated a radical transformation of many of the long-held business practices of the pharmaceutical majors. This phenomenon is what has now come to be known as the ''biotechnology revolution''.

Online publication date: Sun, 13-Jul-2003

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com